Last patient last visit complete in SPL026 Phase IIa clinical trial with topline results expected early in Q1 European patent granted for synthetic manufacturing process of key pipeline candidates LONDON, Dec. 22, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies…
Source